Though lung cancer looks promising a partner is now needed.
ApexOnco Front Page
Recent articles
Deteriorating efficacy and a treatment-related death with Zynlonta plus Columvi spook investors.
More data from onvansertib's phase 2 study fail to convince.
NT-125 is discontinued, while two key Datroway readouts are delayed.
A Pfizer cast-off could become the company's first marketed drug.
Meanwhile, investors await key clinical data.
But BeOne canned its alcestobart deal in May.
Tiragolumab failed the Skyscraper-14 and 03 studies, Roche quietly reveals.
